Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Le Guen Y, Raulin AC, Logue MW, Sherva R, Belloy ME, Eger SJ, Chen A, Kennedy G, Kuchenbecker L, O'Leary JP, Zhang R, Merritt VC, et al.. JAMA, 2023-02-21
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
What this study adds
Evidence grade: Moderate
This is a case-control study of 31,929 participants. In 2,888 people with Alzheimer's and 4,957 controls of African ancestry, those with the ε3/ε4 APOE genotype who also carried a variant called R145C had about 3 times the odds of Alzheimer's (odds ratio 3.01) and a reported onset about 6 years earlier. Reported effect size: OR 3.01 (95% CI 1.87-4.85) for AD among ε3/ε4 carriers with R145C; onset 5.87 years earlier.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Le Guen, Y., Raulin, A. C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., et al. (2023). Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease. JAMA. https://doi.org/10.1001/jama.2023.0268
Vancouver
Le Guen Y, Raulin AC, Logue MW, Sherva R, Belloy ME, Eger SJ, et al. Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease. JAMA. 2023. doi:10.1001/jama.2023.0268. PMID: 36809323.
BibTeX
@article{leguen2023-36809323,
author = {Le Guen, Y. and Raulin, A. C. and Logue, M. W. and Sherva, R. and Belloy, M. E. and Eger, S. J. and Chen, A. and Kennedy, G. and Kuchenbecker, L. and O'Leary, J. P. and Zhang, R. and Merritt, V. C. and others},
title = {{Association of African Ancestry-Specific APOE Missense Variant R145C With Risk of Alzheimer Disease}},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.0268},
pmid = {36809323},
url = {https://doi.org/10.1001/jama.2023.0268}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male).
- In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10-6) and was associated with a reported younger age at AD onset (β, -5.87 years; 95% CI, -8.35 to -3.4 years; P = 3.4 × 10-6).
- No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H.
- Conclusions and relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype.
- With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
Why it matters
In 2,888 people with Alzheimer's and 4,957 controls of African ancestry, those with the ε3/ε4 APOE genotype who also carried a variant called R145C had about 3 times the odds of Alzheimer's (odds ratio 3.01) and a reported onset about 6 years earlier. The link was not seen in other APOE genotypes, and a second variant, R150H, showed no association. The authors call this exploratory and say external validation is needed before it could inform genetic risk assessment for people of African ancestry.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcase-control
- Participants31,929
- Effect sizeOR 3.01 (95% CI 1.87-4.85) for AD among ε3/ε4 carriers with R145C; onset 5.87 years earlier
- Evidence strengthModerate
Limitations
The authors describe this as an exploratory analysis and state that additional external validation is needed before the findings inform genetic risk assessment in individuals of African ancestry.
How this study scored 73/100
Published in a top-tier journal, and it is a case-control study. Scored zero for randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 72 of the 98 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | 4 / 4 | JAMA: journal h-index 1,011 (OpenAlex, 2026-10-29) |
| Study design | 6 / 12 | A case-control study |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 4 / 4 | 31,929 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 51 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.2 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 3 / 6 | Cited 7.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 2 / 4 | Cited 41 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Michael D. Greicius: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 12 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36809323) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 72 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 72 of the 98 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.